Viventia has incorporated many state-of-the-art high-throughput technologies into ImmunoMine™, such as fluorescence macro-confocal live cell screening, multiplexed ELISA, Fluorescence Activated Cell Sorting (FACS), and human tissue microarrays. The ImmunoMine™ platform consists of a rapid screening ‘funnel’, built upon increasingly more rigorous tests designed to rapidly sort therapeutically promising tumor-specific antibodies from those antibodies that react with normal cells. Antibodies that successfully complete ImmunoMine™ screening are added to Viventia’s growing portfolio of tumor-selective human monoclonal antibodies as potential drug development prospects.